China gears up for biosimilars

Multinational biosimilars companies that lack manufacturing facilities in China could find themselves at a disadvantage to local rivals in getting biosimilars approved.

China FDA clarified in a recently released guideline that while biosimilars will be reviewed according to different technical criteria, they are subject to the same new drug approval pathway as innovative biologics...